Gemcitabine and Docetaxel

DRUG5 trials

Sponsors

Asan Medical Center, Hospital Arnau de Vilanova, Medical University of South Carolina, Italian Sarcoma Group

Conditions

Carcinoma, Non-Small-Cell LungOSTEOSARCOMASarcoma

Phase 2

Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy

Asan Medical CenterSarcoma

Start: 2008-09-30End: 2010-09-30Target: 30Updated: 2008-12-12

Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients

Hospital Arnau de VilanovaCarcinoma, Non-Small-Cell Lung

Start: 2007-10-31End: 2011-09-30Updated: 2009-05-21

Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Hospital Arnau de VilanovaCarcinoma, Non-Small-Cell Lung

Start: 2007-10-31End: 2011-10-31Target: 76Updated: 2009-05-21

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

CompletedNCT01593748

Medical University of South CarolinaSarcoma

Start: 2012-09-27End: 2019-04-24Updated: 2020-04-06

Phase II Trial for the Treatment of Relapsed Osteosarcoma

TerminatedNCT02718482

Italian Sarcoma GroupOSTEOSARCOMA

Start: 2016-04-06End: 2019-01-07Updated: 2019-05-13

Related Papers

Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).

Journal of Clinical Oncology2019-05-20

Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).

2015-01-137 citations